Hepatitis C - Human Genome tumbles on mixed drug data

Human Genome tumbles on mixed drug data
Investors Business Daily - BOSTON (MarketWatch) -- Human Genome Sciences shares tumbled Tuesday following the release of mixed Phase II clinical data for its biologic drug candidate to treat hepatitis C, Albuferon. Shares of Human Genome sank 20% to close at $10.89. In a

Restrictive Criteria May Deny Treatment to Most HCV-Infected Drug
Medscape News - NEW YORK (Reuters Health) Mar 21 - The application of multiple exclusion criteria for anti-hepatitis C virus (HCV) treatment may mean that the majority of young injection drug users would be denied treatment, warn a group of clinicians in the March

Ask the Doctor: Hepatitis C sufferers may get unwarranted stigma
Fort Wayne News-Sentinel - Several months ago, I published a column on hepatitis, written by Dr. Alfred McNair, who is a board-certified gastroenterologist on the Coast. I've never received as many responses to an article as I received to that one. Some were congratulatory and

Don't leave it to luck: Wrap it up
Jasper Booster - Jasper Booster Condoms have been around for a very long time. In fact, condom use can be traced back several thousand years. Images from about 1000 BC portray ancient Egyptian studs wearing linen sheaths but it s up for discussion as to whether